When obesity is desirable: A longitudinal study of the Miami HIV-1- infected drug abusers (MIDAS) cohort

Gail Shor-Posner, Adriana Campa, Guoyan Zhang, Navindra Persaud, Maria Jose Miguez-Burbano, Jose Quesada, Mary Ann Fletcher, John Page, Marianna K. Baum

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Despite widespread nutrient deficiencies, a substantial proportion of the MIDAS cohort exhibits obesity, which has been linked to immune dysregulation in other clinical settings. Herein, the effects of obesity on immune function, disease progression, and mortality were evaluated longitudinally in 125 HIV-1-seropositive drug users, with comparison measures in 148 HIV-1-seronegative controls. Data were collected at a community clinic from 1992 to 1996, before administration of highly active antiretroviral therapy. Results indicated that overweight/obesity, defined as body mass index (BMI; kg/m2) ≥27, was evident in 18% of the HIV-1-seropositive patients and 29% of the seronegative patients. At baseline, no significant immunologic differences were observed among lean, nonobese, and obese groups. Over an 18-month period, 60.5% of the nonobese HIV- 1-seropositive patients exhibited a 25% decline in CD4 cell count, compared with 18% of the obese patients (p < .004). During the follow-up period, 38% of the lean and 13% of the nonobese study subjects died of HIV-1-related causes. Measurements of BMI were inversely associated with progression to death, independent of CD4 count <200 cells/mm3 (p < .02). These data suggest that mild-to-moderate obesity in HIV-1-infected chronic drug users does not impair immune function and is associated with better HIV-1-related survival.

Original languageEnglish
Pages (from-to)81-88
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume23
Issue number1
StatePublished - Jan 1 2000

Fingerprint

Drug Users
Longitudinal Studies
HIV-1
Obesity
CD4 Lymphocyte Count
Immune System Diseases
Highly Active Antiretroviral Therapy
Disease Progression
Body Mass Index
Food
Survival
Mortality

Keywords

  • Drug use
  • HIV-infection
  • Mortality
  • Obesity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Shor-Posner, G., Campa, A., Zhang, G., Persaud, N., Miguez-Burbano, M. J., Quesada, J., ... Baum, M. K. (2000). When obesity is desirable: A longitudinal study of the Miami HIV-1- infected drug abusers (MIDAS) cohort. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 23(1), 81-88.

When obesity is desirable : A longitudinal study of the Miami HIV-1- infected drug abusers (MIDAS) cohort. / Shor-Posner, Gail; Campa, Adriana; Zhang, Guoyan; Persaud, Navindra; Miguez-Burbano, Maria Jose; Quesada, Jose; Fletcher, Mary Ann; Page, John; Baum, Marianna K.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 23, No. 1, 01.01.2000, p. 81-88.

Research output: Contribution to journalArticle

Shor-Posner, G, Campa, A, Zhang, G, Persaud, N, Miguez-Burbano, MJ, Quesada, J, Fletcher, MA, Page, J & Baum, MK 2000, 'When obesity is desirable: A longitudinal study of the Miami HIV-1- infected drug abusers (MIDAS) cohort', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 23, no. 1, pp. 81-88.
Shor-Posner, Gail ; Campa, Adriana ; Zhang, Guoyan ; Persaud, Navindra ; Miguez-Burbano, Maria Jose ; Quesada, Jose ; Fletcher, Mary Ann ; Page, John ; Baum, Marianna K. / When obesity is desirable : A longitudinal study of the Miami HIV-1- infected drug abusers (MIDAS) cohort. In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 2000 ; Vol. 23, No. 1. pp. 81-88.
@article{9c0c1da170e64cba95d04ad24ae4dcdf,
title = "When obesity is desirable: A longitudinal study of the Miami HIV-1- infected drug abusers (MIDAS) cohort",
abstract = "Despite widespread nutrient deficiencies, a substantial proportion of the MIDAS cohort exhibits obesity, which has been linked to immune dysregulation in other clinical settings. Herein, the effects of obesity on immune function, disease progression, and mortality were evaluated longitudinally in 125 HIV-1-seropositive drug users, with comparison measures in 148 HIV-1-seronegative controls. Data were collected at a community clinic from 1992 to 1996, before administration of highly active antiretroviral therapy. Results indicated that overweight/obesity, defined as body mass index (BMI; kg/m2) ≥27, was evident in 18{\%} of the HIV-1-seropositive patients and 29{\%} of the seronegative patients. At baseline, no significant immunologic differences were observed among lean, nonobese, and obese groups. Over an 18-month period, 60.5{\%} of the nonobese HIV- 1-seropositive patients exhibited a 25{\%} decline in CD4 cell count, compared with 18{\%} of the obese patients (p < .004). During the follow-up period, 38{\%} of the lean and 13{\%} of the nonobese study subjects died of HIV-1-related causes. Measurements of BMI were inversely associated with progression to death, independent of CD4 count <200 cells/mm3 (p < .02). These data suggest that mild-to-moderate obesity in HIV-1-infected chronic drug users does not impair immune function and is associated with better HIV-1-related survival.",
keywords = "Drug use, HIV-infection, Mortality, Obesity",
author = "Gail Shor-Posner and Adriana Campa and Guoyan Zhang and Navindra Persaud and Miguez-Burbano, {Maria Jose} and Jose Quesada and Fletcher, {Mary Ann} and John Page and Baum, {Marianna K.}",
year = "2000",
month = "1",
day = "1",
language = "English",
volume = "23",
pages = "81--88",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "1",

}

TY - JOUR

T1 - When obesity is desirable

T2 - A longitudinal study of the Miami HIV-1- infected drug abusers (MIDAS) cohort

AU - Shor-Posner, Gail

AU - Campa, Adriana

AU - Zhang, Guoyan

AU - Persaud, Navindra

AU - Miguez-Burbano, Maria Jose

AU - Quesada, Jose

AU - Fletcher, Mary Ann

AU - Page, John

AU - Baum, Marianna K.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Despite widespread nutrient deficiencies, a substantial proportion of the MIDAS cohort exhibits obesity, which has been linked to immune dysregulation in other clinical settings. Herein, the effects of obesity on immune function, disease progression, and mortality were evaluated longitudinally in 125 HIV-1-seropositive drug users, with comparison measures in 148 HIV-1-seronegative controls. Data were collected at a community clinic from 1992 to 1996, before administration of highly active antiretroviral therapy. Results indicated that overweight/obesity, defined as body mass index (BMI; kg/m2) ≥27, was evident in 18% of the HIV-1-seropositive patients and 29% of the seronegative patients. At baseline, no significant immunologic differences were observed among lean, nonobese, and obese groups. Over an 18-month period, 60.5% of the nonobese HIV- 1-seropositive patients exhibited a 25% decline in CD4 cell count, compared with 18% of the obese patients (p < .004). During the follow-up period, 38% of the lean and 13% of the nonobese study subjects died of HIV-1-related causes. Measurements of BMI were inversely associated with progression to death, independent of CD4 count <200 cells/mm3 (p < .02). These data suggest that mild-to-moderate obesity in HIV-1-infected chronic drug users does not impair immune function and is associated with better HIV-1-related survival.

AB - Despite widespread nutrient deficiencies, a substantial proportion of the MIDAS cohort exhibits obesity, which has been linked to immune dysregulation in other clinical settings. Herein, the effects of obesity on immune function, disease progression, and mortality were evaluated longitudinally in 125 HIV-1-seropositive drug users, with comparison measures in 148 HIV-1-seronegative controls. Data were collected at a community clinic from 1992 to 1996, before administration of highly active antiretroviral therapy. Results indicated that overweight/obesity, defined as body mass index (BMI; kg/m2) ≥27, was evident in 18% of the HIV-1-seropositive patients and 29% of the seronegative patients. At baseline, no significant immunologic differences were observed among lean, nonobese, and obese groups. Over an 18-month period, 60.5% of the nonobese HIV- 1-seropositive patients exhibited a 25% decline in CD4 cell count, compared with 18% of the obese patients (p < .004). During the follow-up period, 38% of the lean and 13% of the nonobese study subjects died of HIV-1-related causes. Measurements of BMI were inversely associated with progression to death, independent of CD4 count <200 cells/mm3 (p < .02). These data suggest that mild-to-moderate obesity in HIV-1-infected chronic drug users does not impair immune function and is associated with better HIV-1-related survival.

KW - Drug use

KW - HIV-infection

KW - Mortality

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=0034088997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034088997&partnerID=8YFLogxK

M3 - Article

C2 - 10708060

AN - SCOPUS:0034088997

VL - 23

SP - 81

EP - 88

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 1

ER -